Dexcom Inc.
DexCom Announces Preliminary FY 2023 Revenue and FY 2024 Outlook
Summary
DexCom, Inc. reported preliminary, unaudited revenue for the fourth quarter and fiscal year 2023, showing an increase of 26% and 24% respectively. The company also provided its initial financial outlook for fiscal year 2024, anticipating total revenue between $4.15 billion and $4.35 billion. Additionally, DexCom announced the submission of its new glucose sensor, Stelo, to the FDA for review, with an expected U.S. launch in summer 2024.
Profitelligence Alerts
Get alerts for DXCM
Be first to know when Dexcom Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Dexcom Inc.
Dexcom Inc. is a prominent player in the medical technology sector, specializing in continuous glucose monitoring (CGM) systems for diabetes management. The company's primary function is to develop and distribute innovative CGM devices that provide real-time glucose readings, allowing individuals with diabetes to make informed decisions about their health. Dexcom’s products play a critical role in healthcare by offering an alternative to traditional fingerstick testing, thus improving quality of life for many users. The company impacts several sectors, most notably within healthcare and technology, by integrating advanced data analytics and wireless technology into its monitoring systems. This not only aids individuals in managing their glucose levels but also supports healthcare providers in delivering better patient care through data-driven insights. In the financial market, Dexcom Inc. is recognized for its contributions to the growing field of digital health solutions. The company has established itself as a leader in its niche, continuously pushing the boundaries of technology to offer more precise and user-friendly glucose monitoring options. Founded in 1999 and headquartered in San Diego, California, Dexcom remains at the forefront of diabetes management solutions.
Official SEC Documents
Advertisement